301 related articles for article (PubMed ID: 25239521)
1. A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung.
Yang JJ; Huang C; Chen GY; Song Y; Cheng Y; Yan HH; Zhou Q; Wu YL
BMC Cancer; 2014 Sep; 14():684. PubMed ID: 25239521
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma.
An X; Xue C; Chen M; Ni M; Ma H; Tian L; Huang R; Li X; Ye Y; Qin T; Dong P; Li Z; Peng J; Yao K; Zhou F; Liu Z; Shi Y
BJU Int; 2024 Jul; 134(1):63-71. PubMed ID: 38009394
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.
Bachet JB; Chibaudel B; Bonnetain F; Validire P; Hammel P; André T; Louvet C;
BMC Cancer; 2015 Oct; 15():653. PubMed ID: 26445094
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175.
Gentzler RD; Mohindra NA; Jalal SI; Reckamp KL; Hall RD; Hanna NH; Chae YK; Koczywas M; Helenowski IB; Patel JD
Oncologist; 2024 Jan; 29(1):47-56. PubMed ID: 37390616
[TBL] [Abstract][Full Text] [Related]
5. Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis.
Otsubo K; Kishimoto J; Kenmotsu H; Minegishi Y; Ichihara E; Shiraki A; Kato T; Atagi S; Horinouchi H; Ando M; Kondoh Y; Kusumoto M; Ichikado K; Yamamoto N; Nakanishi Y; Okamoto I
Clin Lung Cancer; 2018 Jan; 19(1):e5-e9. PubMed ID: 28687482
[TBL] [Abstract][Full Text] [Related]
6. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.
Ko AH; Murphy PB; Peyton JD; Shipley DL; Al-Hazzouri A; Rodriguez FA; Womack MS; Xiong HQ; Waterhouse DM; Tempero MA; Guo S; Lane CM; Earwood C; DeBusk LM; Bendell JC
Oncologist; 2017 Dec; 22(12):1427-e129. PubMed ID: 28935773
[TBL] [Abstract][Full Text] [Related]
7. A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q).
Nakamichi S; Kubota K; Matsuyama K; Misumi T; Kozuki T; Sugawara S; Naoki K; Kobayashi N; Shukuya T; Shimokawa T; Ishihara M; Wakui H; Hosomi Y; Tanaka H; Saito H; Hosokawa S; Takiguchi Y; Kasai T; Nokihara H; Morita R; Aono H; Furuya N; Okamoto H
Clin Lung Cancer; 2024 Jan; 25(1):85-90. PubMed ID: 37981477
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study.
Zhang J; Pan Y; Shi Q; Zhang G; Jiang L; Dong X; Gu K; Wang H; Zhang X; Yang N; Li Y; Xiong J; Yi T; Peng M; Song Y; Fan Y; Cui J; Chen G; Tan W; Zang A; Guo Q; Zhao G; Wang Z; He J; Yao W; Wu X; Chen K; Hu X; Hu C; Yue L; Jiang D; Wang G; Liu J; Yu G; Li J; Bai J; Xie W; Zhao W; Wu L; Zhou C
Cancer Commun (Lond); 2022 Jan; 42(1):3-16. PubMed ID: 34699693
[TBL] [Abstract][Full Text] [Related]
9. Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes.
Villaruz LC; Socinski MA
Eur J Cancer; 2016 Mar; 56():162-171. PubMed ID: 26875112
[TBL] [Abstract][Full Text] [Related]
10. Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial).
Zhou N; Li X; Yang Y; Tan S; Zhang S; Huang Q; Gou H
BMC Cancer; 2023 Aug; 23(1):729. PubMed ID: 37550655
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract Cancers.
Gedela S; Munot P; Vaidyanathan A; Joarder R; Chaugule D; Parulekar M; Nashikkar C; Ghadi A; Vadodaria D; Goel M; Patkar S; Mandavkar S; Ramaswamy A; Bhargava P; Srinivas S; Ostwal V
J Gastrointest Cancer; 2024 Mar; 55(1):263-269. PubMed ID: 37368175
[TBL] [Abstract][Full Text] [Related]
12. Optimizing perioperative treatment for potentially resectable stage III squamous cell lung carcinoma: promising results of a condensed four-cycle regimen with tislelizumaband chemotherapy.
Shan J; Liu Z; Chen S; Du C; Li B; Ruan L; Kong M; Wang L; Du M; Shi S; Qiao G; Tian T; Tu Z
BMC Med; 2024 Jun; 22(1):234. PubMed ID: 38853265
[TBL] [Abstract][Full Text] [Related]
13. [Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: a prospective phaseⅡstudy].
Chen XR; Xie ZC; Lu HZ; Yang JL; Gui L
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):321-328. PubMed ID: 38599639
[No Abstract] [Full Text] [Related]
14. Comparative effectiveness and safety of
Mudad R; Patel MB; Margunato-Debay S; Garofalo D; Lal LS
Lung Cancer (Auckl); 2017; 8():179-190. PubMed ID: 29089791
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study.
Jain MM; Gupte SU; Patil SG; Pathak AB; Deshmukh CD; Bhatt N; Haritha C; Govind Babu K; Bondarde SA; Digumarti R; Bajpai J; Kumar R; Bakshi AV; Bhattacharya GS; Patil P; Subramanian S; Vaid AK; Desai CJ; Khopade A; Chimote G; Bapsy PP; Bhowmik S
Breast Cancer Res Treat; 2016 Feb; 156(1):125-34. PubMed ID: 26941199
[TBL] [Abstract][Full Text] [Related]
16. First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.
Gupta N; Hatoum H; Dy GK
Int J Nanomedicine; 2014; 9():209-21. PubMed ID: 24399877
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Buisseret L; Loirat D; Aftimos P; Maurer C; Punie K; Debien V; Kristanto P; Eiger D; Goncalves A; Ghiringhelli F; Taylor D; Clatot F; Van den Mooter T; Ferrero JM; Bonnefoi H; Canon JL; Duhoux FP; Mansi L; Poncin R; Barthélémy P; Isambert N; Denis Z; Catteau X; Salgado R; Agostinetto E; de Azambuja E; Rothé F; Craciun L; Venet D; Romano E; Stagg J; Paesmans M; Larsimont D; Sotiriou C; Ignatiadis M; Piccart-Gebhart M
Nat Commun; 2023 Nov; 14(1):7018. PubMed ID: 37919269
[TBL] [Abstract][Full Text] [Related]
18. A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial).
Koizumi W; Morita S; Sakata Y
Jpn J Clin Oncol; 2015 Mar; 45(3):303-6. PubMed ID: 25516635
[TBL] [Abstract][Full Text] [Related]
19. Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.
Goel S; Tan AR; Rugo HS; Aftimos P; Andrić Z; Beelen A; Zhang J; Yi JS; Malik R; O'Shaughnessy J
Future Oncol; 2022 Oct; 18(33):3701-3711. PubMed ID: 36135712
[TBL] [Abstract][Full Text] [Related]
20. Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient.
Okano Y; Kunishige M; Kondo Y; Kadota N; Morishita A; Naruse K; Machida H; Hatakeyama N; Hino H; Shinohara T; Sakiyama S; Takeuchi E
Thorac Cancer; 2022 Feb; 13(3):510-513. PubMed ID: 34931476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
